H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $33 and keeps a Buy rating on the shares. The firm cites the company’s equity financing for the target drop.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics’ NX-1607 Study: A Potential Game-Changer in Cancer Treatment
- Nurix Therapeutics Advances NX-5948 Study in B-cell Malignancies
- Nurix Therapeutics’ NX-2127 Study: A Potential Game-Changer in B-cell Malignancy Treatment
- Nurix Therapeutics’ NX-5948 Study: A Potential Game-Changer in Drug Delivery
- 3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts